<div id="readability-page-1">Sentinel Trust Co. LBA purchased a new stake in shares of Roche Holding AG (OTCMKTS:RHHBY - Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 21,507 shares of the company's stock, valued at approximately $878,000.<ul><li>3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.</li></ul>Several other institutional investors and hedge funds have also made changes to their positions in the stock. Oakworth Capital Inc. acquired a new stake in Roche in the 3rd quarter valued at about $57,000. First Horizon Advisors Inc. increased its stake in shares of Roche by 81.2% in the second quarter. First Horizon Advisors Inc. now owns 1,843 shares of the company's stock worth $75,000 after acquiring an additional 826 shares during the last quarter. Salomon &amp; Ludwin LLC increased its holdings in Roche by 256.6% in the third quarter. Salomon &amp; Ludwin LLC now owns 2,853 shares of the company's stock worth $129,000 after buying an additional 2,053 shares during the last quarter. Enterprise Financial Services Corp acquired a new position in Roche during the second quarter worth $208,000. Finally, FineMark National Bank &amp; Trust acquired a new position in Roche during the second quarter valued at approximately $210,000. <h2>Key Roche News</h2>Here are the key news stories impacting Roche this week:<ul> <li>Positive Sentiment: Roche reported strong 2025 results — 7% sales growth — and guided to mid-single-digit sales growth and high-single-digit core EPS growth for 2026; management also plans to raise the dividend, supporting longer-term shareholder value. Ad-hoc announcement: Roche reports strong 2025 results with 7% sales growth</li> <li>Positive Sentiment: Roche’s pipeline — especially obesity and cardiovascular programs — is highlighted as a potential growth driver and a credible challenger in the GLP‑1 market, underpinning the “buy” thesis for longer-term upside. Roche's Full-Year Earnings: Solid, No Alarms - Obesity Promise Makes The Buy Case</li> <li>Neutral Sentiment: Earnings essentially matched expectations and failed to excite the market, leaving the stock rangebound as investors await clearer proof of pipeline monetization. Drugmakers Roche and Sanofi talk up their pipelines, as earnings fail to excite</li> <li>Neutral Sentiment: Goldman Sachs assigned a “Hold” to Roche (RHHVF/RHHBY), reflecting a neutral view that likely limited buying interest despite the upbeat guidance. Roche Holding AG (RHHVF) Gets a Hold from Goldman Sachs</li> <li>Negative Sentiment: Currency (FX) headwinds materially weighed on reported results, reducing the headline impact of underlying growth and creating near-term earnings uncertainty that pressured the stock. Roche's annual results hit by currency headwinds</li> </ul><h2>Roche Stock Performance</h2><ul><li>Viking Therapeutics: Could GLP-1 Maker Be Acquired Pre-Approval?</li></ul>Shares of RHHBY opened at $56.75 on Friday. The company has a debt-to-equity ratio of 0.80, a quick ratio of 1.02 and a current ratio of 1.29. Roche Holding AG has a 12 month low of $34.75 and a 12 month high of $57.29. The firm has a fifty day simple moving average of $51.76 and a 200 day simple moving average of $45.39. <h2>Wall Street Analyst Weigh In</h2>Several equities research analysts have recently weighed in on the company. Barclays raised Roche from an &#34;equal weight&#34; rating to an &#34;overweight&#34; rating in a research report on Tuesday, January 6th. Citigroup initiated coverage on Roche in a research report on Tuesday. They issued a &#34;buy&#34; rating for the company. Deutsche Bank Aktiengesellschaft upgraded Roche from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Tuesday, November 11th. Morgan Stanley reaffirmed an &#34;underweight&#34; rating on shares of Roche in a research note on Tuesday, December 2nd. Finally, The Goldman Sachs Group upgraded Roche from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Thursday, January 15th. Two equities research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Roche has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $57.00.<ul><li>NVIDIA Invested in These 2 AI Stocks, Should You? </li></ul>Get Our Latest Analysis on Roche<h2>Roche Company Profile</h2> (Free Report)Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY OTCMKTS: RHHBY. In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.<h2>Featured Stories</h2><ul><li>Five stocks we like better than Roche</li><li>Stock market legend warns: “An Ominous Day Is Coming for the Markets…”</li><li>Another reason you need to own gold… [running out]</li><li>Trump’s Final Shocking Act Begins February 24</li><li>NEW: Gold makes history</li><li>Deutsche Bank Just Raised Their Gold Target to $6,000</li></ul>Want to see what other hedge funds are holding RHHBY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Roche Holding AG (OTCMKTS:RHHBY - Free Report).<img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU9UQ01LVFMmU3ltYm9sPVJISEJZ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU9UQ01LVFMmU3ltYm9sPVJISEJZ"/>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.<h2>Should You Invest $1,000 in Roche Right Now?</h2>Before you consider Roche, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roche wasn't on the list.While Roche currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here </div>

Sentinel Trust Co. LBA acquired 21,507 shares of Roche Holding AG (OTCMKTS:RHHBY) valued at approximately $878,000 during Q3, as disclosed to the SEC. Other institutional investors also adjusted their positions in Roche. The company reported strong 2025 results with 7% sales growth and plans to raise dividends. However, currency headwinds impacted earnings, leading to a neutral sentiment among analysts, with Goldman Sachs assigning a "Hold" rating. Roche's stock has a consensus rating of "Moderate Buy" and a price target of $57.00.

Market Beat

Proshares Ultra Nasdaq Biotech

iShares US Pharma

ROCHE HOLDINGS AG

ALPS Medical Breakthrough

Health Care Select Sector SPDR

SPDR S&P Biotech

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

VG Health

Roche

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

Sentinel Trust Co. LBA Buys Shares of 21,507 Roche Holding AG $RHHBY